Susanne Briest
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Susanne Briest has a total of 2 co-authors. Here are the top co-authors by number of shared publications:
- Antonio C. Wolff
Johns Hopkins University, Baltimore, MD
1 shared publication - Nancy E. Davidson
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
1 shared publication
Latest Publications
- 1 September 2007
- Published by Taylor & Francis in Expert Review of Anticancer Therapy
- Vol. 7 (9) , 1243-1253
Insights on adjuvant endocrine therapy for premenopausal and postmenopausal breast cancer
In 2005, cancer accounted for 13% of all deaths worldwide. Breast cancer is the number-one cause of cancer-related death among women in the USA, affecting 178,480 of them in 2007. As 75% of tumors in postmenopausal women and half in premenopausal women express estrogen receptor, endocrine therapy plays a significant role as a systemic treatment. Robust datasets have demonstrated the impact of tamoxifen in reducing breast cancer recurrence and mortality, regardless of the age of the patient. Other estrogen-deprivation strategies, such as aromatase inhibitors in postmenopausal women and luteinizing hormone-releasing hormone agonists in premenopausal women, are being increasingly used for estrogen receptor-positive breast cancer. This review discusses basic principles regarding endocrine therapy, the need for accurate estrogen receptor testing and the role of menopause in therapy selection.
- 1 September 2007
- Published by Taylor & Francis in Expert Review of Anticancer Therapy
- Vol. 7 (9) , 1243-1253
Insights on adjuvant endocrine therapy for premenopausal and postmenopausal breast cancer
In 2005, cancer accounted for 13% of all deaths worldwide. Breast cancer is the number-one cause of cancer-related death among women in the USA, affecting 178,480 of them in 2007. As 75% of tumors in postmenopausal women and half in premenopausal women express estrogen receptor, endocrine therapy plays a significant role as a systemic treatment. Robust datasets have demonstrated the impact of tamoxifen in reducing breast cancer recurrence and mortality, regardless of the age of the patient. Other estrogen-deprivation strategies, such as aromatase inhibitors in postmenopausal women and luteinizing hormone-releasing hormone agonists in premenopausal women, are being increasingly used for estrogen receptor-positive breast cancer. This review discusses basic principles regarding endocrine therapy, the need for accurate estrogen receptor testing and the role of menopause in therapy selection.
- 8 May 2007
- Published by Springer Nature in Reviews in Endocrine and Metabolic Disorders
- Vol. 8 (3) , 215-228
Aromatase inhibitors for breast cancer
- 8 May 2007
- Published by Springer Nature in Reviews in Endocrine and Metabolic Disorders
- Vol. 8 (3) , 215-228
Aromatase inhibitors for breast cancer